Subscribe to RSS
DOI: 10.1055/s-2000-8998
The Second European Endoscopy Forum (Sintra, Portugal, 17 - 18 June 1999): Twenty Questions on the Esophagogastric Junction
Publication History
Publication Date:
31 December 2000 (online)
![](https://www.thieme-connect.de/media/endoscopy/200005/lookinside/thumbnails/10.1055-s-2000-8998-1.jpg)
Introduction
The purpose of the Second European Endoscopy Forum was to agree on definitions and to discuss the pathogenesis of Barrett's esophagus (BE) and associated adenocarcinoma. It was agreed that the term “Barrett's esophagus” was a good one, since although our current concepts of this condition do not necessarily coincide with those originally described by Barrett, the use of the term is generally understood, and it is concise. The Symposium generally focused on the diagnosis and endoscopic management of BE, as well as on cost-effectiveness aspects.
References
- 1 Barrett NR. The lower oesophagus lined by columnar epithelium. Surgery. 1957; 41 881-894
- 2 Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar-lined Barrett's esophagus: comparison of population based clinical and autopsy findings. Gastroenterology. 1990; 99 918-922
- 3 Chalsani N, Woo JM, Hunter JG, Waring SP. Significance of intestinal metaplasia in different areas of the oesophagus including oesophagogastric junction. Dig Dis Sci. 1997; 42 603-607
- 4 Hirota WK, Loughney TM, Lazas DJ, et al. Specialized intestinal metaplasia, dysplasia and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology. 1999; 116 277-285
- 5 Iascone C, DeMeester TR, Little AG, Skinner DB. Barrett's esophagus: functional assessment, proposed pathogenesis, and surgical therapy. Arch Surg. 1983; 118 543-549
- 6 Kahrilas PJ. Anatomy and physiology of the gastroesophageal junction. Gastroenterol Clin North Am. 1997; 3 467-485
- 7 Levine DS. Management of dysplasia in the columnar-lined esophagus. Gastroenterol Clin North Am. 1997; 3 613-634
- 8 Ormsby AH, Goldblum JR, Richter JE, et al. Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach. Hum Pathol. 1999; 30 288-294
- 9 Spechler SJ. The columnar-lined esophagus: histology, terminology and clinical issues. Gastroenterol Clin North Am. 1997; 26 445-466
- 10 Spechler SJ. The role of gastric carditis in metaplasia and neoplasia at the gastroesophageal junction. Gastroenterology. 1999; 117 218-228
- 11 Spechler SJ, Goyal RK. Barrett's esophagus. N Engl J Med. 1986; 315 362-371
- 12 Van der Burgh A, Dees J, Hopp WCJ, van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut. 1996; 39 5-8
- 13 Wijnhoven BP, Siersema PD, Hop WC, et al. Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity (Rotterdam Oesophageal Tumour Group). Br J Surg. 1999; 86 529-535
- 14 Wright TA. High-grade dysplasia in Barrett's oesophagus. Br J Surg. 1997; 84 760-766
- 15 Bytzer P, Christensen PB, Damkier P, et al. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study. Am J Gastroenterol. 1999; 94 86-91
- 16 Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998; 83 2049-2053
- 17 Dolan K, Sutton R, Walker SJ, et al. New classification of oesophageal and gastric carcinomas derived from changing patterns in epidemiology. Br J Cancer. 1999; 80 834-842
- 18 Hansen S, Wiig JN, Giercksky KE, Tretli S. Esophageal and gastric carcinoma in Norway, 1958 - 1992: incidence, time trend variability according to morphological subtypes and organ subsites. Int J Cancer. 1997; 71 340-344
-
19 National Cancer Institute.
Surveillance, Epidemiology, and End Results. SEER*Stat for Windows 95/NT, Version 1.1: SEER cancer incidence public-use database, 1993 - 1995. Bethesda, MD; US Department of Health and Human Services, 1997 - 20 Champion G, Richter JE, Vaezi MF, et al. Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus. Gastroenterology. 1994; 107 747-754
- 21 Collen MJ, Lewis JH, Benjamin SB. Gastric acid hypersecretion in refractory gastroesophageal reflux disease. Gastroenterology. 1990; 98 654-661
- 22 Eisen GM, Sandler RS, Murray S, Gottfried M. The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus. Am J Gastroenterol. 1997; 92 27-31
- 23 El-Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut. 1998; 43 333
- 24 El-Serag HB, Sonnenberg A. Associations among different forms of gastroesophageal reflux disease. Gut. 1997; 41 594-599
- 25 Galmiche JP, Janssens J. The pathophysiology of gastro-oesophageal reflux disease: an overview. Scand J Gastroenterol. 1995; 30 (Suppl 211) 7-18
- 26 Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999; 340 825-831
- 27 Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis. 1976; 21 953-956
-
28 Sonnenberg A, El-Serag HB.
Epidemiology of gastroesophageal reflux disease . In: Büchler MW, Farthmann EH Progress in Surgery, vol. 23. Basle; Karger 1997: 36 - 29 Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ III. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology. 1992; 102 1259-1268
- 30 Burtin P, Napoleon B, Palazzo L, et al. Interobserver agreement in endoscopic ultrasonography staging of esophageal and cardia cancer. Gastrointest Endosc. 1996; 43 20-24
- 31 Canto M. Vital staining and Barrett's esophagus. Gastrointest Endosc. 1999; 49 6
- 32 Eloubeidi MA, Provenzale D. Does this patient have Barrett's esophagus? The utility of predicting Barrett's esophagus at the index endoscopy. Am J Gastroenterol. 1999; 94 937-943
- 33 Ellis KK, Oehlke M, Helfand M, Lieberman D. Management of symptoms of gastroesophageal reflux disease: does endoscopy influence medical management?. Am J Gastroenterol. 1997; 92 1472-1474
- 34 Ellis FH, Loda M. Role of surveillance endoscopy, biopsy and biomarkers in early detection of Barrett' s adenocarcinoma. Dis Esophagus. 1997; 10 165-171
- 35 Murata Y. The role of endoscopic ultrasonography for gastric cancer in the cardiac area [in Japanese]. Nippon Geka Gakkai Zasshi. 1998; 99 564-568
- 36 Tytgat GN. Does endoscopic surveillance in esophageal columnar metaplasia (Barrett's esophagus) have any value?. Endoscopy. 1995; 27 19-26
- 37 Tytgat GN. Endoscopic features of the columnar-lined esophagus. Gastroenterol Clin North Am. 1997; 3 507-517
- 38 Fennerty MB. Perspectives on endoscopic eradication of Barrett's esophagus: who are appropriate candidates and what is the best method?. Gastrointest Endosc. 1999; 49 (3) 24-28
- 39 Gossner L, Stolte M, Sroka R, et al. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. Gastroenterology. 1998; 114 448-455
- 40 Lightdale CJ. Ablation therapy for Barrett's esophagus: is it time to choose our weapons?. Gastrointest Endosc. 1999; 49 122-125
- 41 Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest Endosc. 1999; 49 1-7
- 42 Van den Boogert J, van Hillegersberg R, Siersema PD, et al. Endoscopic ablation therapy for Barrett's esophagus with high-grade dysplasia: a review. Am J Gastroenterol. 1999; 94 1153-1160
- 43 Van Laethem JL, Cremer M, Peny MO, et al. Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid-term results. Gut. 1998; 43 747-751
- 44 Provenzale D, Kemp JA, Arora S, Wong JB. A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol. 1994; 89 670-680
-
45 Sonnenberg A.
Esophageal diseases. In: Everhart JE Digestive diseases in the United States: epidemiology and impact (US Department of Health and Human Services, NIH publication no. 94-1447). Washington, DC; US Government Printing Office 1994: 356 - 46 Sonnenberg A, El-Serag HB. Economic aspects of endoscopic screening for intestinal precancerous conditions. Gastrointest Endosc Clin North Am. 1997; 7 165-184
- 47 Sonnenberg A, Delco F, El-Serag HB. Empirical therapy versus diagnostic tests in gastroesophageal reflux disease: a medical decision analysis. Dig Dis Sci. 1998; 43 1001-1008
- 48 Wright TA, Gray MR, Morris AI, et al. Cost-effectiveness of detecting Barrett's cancer. Gut. 1996; 39 574-579
M.D. R. Lambert
International Agency for Research on Cancer
150, Cours A. Thomas
Lyon 69003
France
Phone: +33-4-72110147
Email: lambert@iarc. fr